Chemical subgroup
R03DX – Andere Mittel bei obstruktiven Atemwegserkrankungen zur systemischen Anwendung
13Decisions
19Patient groups
Added benefit by patient group
- Considerable1
- Minor3
- Non-quantifiable1
- Not proven14
Decisions, newest first
- 2026-10-01ExdensurDepemokimabNot proven
- 2026-10-01ExdensurDepemokimabNot proven: 2 of 2 patient groups
- 2026-09-03NucalaMepolizumabNot proven
- 2026-05-07TezspireTezepelumabNon-quantifiable
- 2025-05-15FasenraBenralizumabNot proven: 2 of 2 patient groups
- 2023-05-12TezspireTezepelumabNot proven: 2 of 2 patient groups
- 2022-05-19NucalaMepolizumabConsiderable
- 2022-05-19NucalaMepolizumabNot proven
- 2022-05-19NucalaMepolizumabNot proven
- 2019-03-22NucalaMepolizumabNot proven
- 2018-08-02FasenraBenralizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2017-07-06CinqaeroReslizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-07-21NucalaMepolizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
Data status: 2026-10-29